Advanced Search
Submit Manuscript Volume 22, No 12, Dec 2012
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 22 Issue 12, December 2012: 1712-1715
Song Wu1,2,3,4,*, Xiaojuan Sun1,4,5,*, Weimin Zhu1,*, Yi Huang1,4,*, Lisha Mou6,*, Mingming Liu7, Xia Li7/sup>, Feiyang Li1, Xianxin Li6, Yong Zhang7
1Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China
2Institute of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China
3The Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
4Shenzhen Key Laboratory of Genitourinary Tumor, Shenzhen Second People's Hospital, Shenzhen, Guangdong 518035, China
5Shenzhen Engineering lab of Tumor Clinical Immune Gene Therapy, Shenzhen Second People's Hospital, Shenzhen, Guangdong, 518035, China
6Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, China
7BGI-Shenzhen, Shenzhen, Guangdong 518083, China
8Shenzhen First People's Hospital, Shenzhen, Guangdong 518001, China
Correspondence: Zhiming Cai, Daping Wang,(caizhiming2000@yahoo.com.cn; dapingwang1963@qq.com)
Cell Research (2012) 22:1712-1715. doi:10.1038/cr.2012.149; published online 13 November 2012